Patents by Inventor Jean-Marc Herbert

Jean-Marc Herbert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8703738
    Abstract: The invention concerns novel biotinylated hexadecasaccharides of general formula (I) wherein: Biot is a biotin derivative; R, R1 and R2, represent independently of one another a C1-C6 alkoxy or and —OSO3; R3 represents a C1-C6 alkoxy or an —OSO3, or R3 constitutes a —O—CH2— bridge; Pe represents a saccharide concatenation; as well as their pharmaceutically acceptable salts, and their use as medicines.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: April 22, 2014
    Assignee: SANOFI
    Inventors: Philippe Duchaussoy, Jean Pascal Herault, Jean Marc Herbert, Maurice Petitou, Pierre Savi
  • Patent number: 8557968
    Abstract: The invention concerns novel biotinylated hexadecasaccharides of general formula (I) wherein: Biot is a biotin derivative; R, R1 and R2, represent independently of one another a C1-C6 alkoxy or and —OSO3; R3 represents a C1-C6 alkoxy or an —OSO3, or R3 constitutes a —O—CH2— bridge; Pe represents a saccharide concatenation; as well as their pharmaceutically acceptable salts, and their use as medicines.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: October 15, 2013
    Assignee: Sanofi
    Inventors: Philippe Duchaussoy, Jean Pascal Herault, Jean Marc Herbert, Maurice Petitou, Pierre Savi
  • Publication number: 20130004551
    Abstract: The invention concerns novel biotinylated hexadecasaccharides of general formula (I) wherein: Biot is a biotin derivative; R, R1 and R2, represent independently of one another a C1-C6 alkoxy or and —OSO3; R3 represents a C1-C6 alkoxy or an —OSO3, or R3 constitutes a —O—CH2— bridge; Pe represents a saccharide concatenation; as well as their pharmaceutically acceptable salts, and their use as medicines.
    Type: Application
    Filed: September 12, 2012
    Publication date: January 3, 2013
    Applicant: SANOFI
    Inventors: Philippe Duchaussoy, Jean Pascal Herault, Jean Marc Herbert, Maurice Petitou, Pierre Savi
  • Patent number: 8318696
    Abstract: The present invention relates to novel synthetic polysaccharides with antithrombotic activity exhibiting at least one covalent bond with biotin or a biotin derivative and to a process employing avidin or streptavidin which makes it possible to neutralize these polysaccharides.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: November 27, 2012
    Assignee: Sanofi
    Inventors: Philippe Duchaussoy, Jean-Marc Herbert, Maurice Petitou, Pierre Savi
  • Publication number: 20110251194
    Abstract: The disclosure concerns heterobicyclic compounds of general formula (I) and acid addition salts, hydrates and solvates thereof, as well as enantiomers, diastereoisomers and mixtures thereof. Methods for preparing the compounds, pharmaceutical compositions, and methods of treatment also are disclosed.
    Type: Application
    Filed: January 7, 2011
    Publication date: October 13, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Claude BERNHART, Gary MCCORT, Samir JEGHAM, Jean Marc HERBERT, Pierre CASELLAS, Monsif BOUABOULA, Olivier DUCLOS
  • Publication number: 20110144042
    Abstract: The present invention relates to novel synthetic polysaccharides with antithrombotic activity exhibiting at least one covalent bond with biotin or a biotin derivative and to a process employing avidin or streptavidin which makes it possible to neutralize these polysaccharides.
    Type: Application
    Filed: February 28, 2011
    Publication date: June 16, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Philippe Duchaussoy, Jean-Marc Herbert, Maurice Petitou, Pierre Savi
  • Patent number: 7943595
    Abstract: The present invention relates to novel synthetic polysaccharides with antithrombotic activity exhibiting at least one covalent bond with biotin or a biotin derivative and to a process employing avidin or streptavidin which makes it possible to neutralize these polysaccharides.
    Type: Grant
    Filed: January 14, 2005
    Date of Patent: May 17, 2011
    Assignee: sanofi-aventis
    Inventors: Philippe Duchaussoy, Jean Marc Herbert, Maurice Petitou, Pierre Savi
  • Patent number: 7919614
    Abstract: Synthetic polysaccharides are disclosed containing 8-24 monosaccharide units made up of a concatenation of disaccharides consisting of a uronic acid and a hexose, wherein the hydroxyl groups of the polysaccharides are etherified with a C1-6 alkyl group or esterified in the form of a sulpho group, each disaccharide being at least monoetherified; and salts thereof, are disclosed.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: April 5, 2011
    Assignees: Sanofi-Aventis, Azko Nobel
    Inventors: Philippe Duchaussoy, Jean Marc Herbert, Guy Jaurand, Maurice Petitou, Constant Van Boeckel
  • Publication number: 20100279960
    Abstract: The invention concerns novel biotinylated hexadecasaccharides of general formula (I) wherein: Biot is a biotin derivative; R, R1 and R2, represent independently of one another a C1-C6 alkoxy or and —OSO3; R3 represents a C1-C6 alkoxy or an —OSO3, or R3 constitutes a —O—CH2— bridge; Pe represents a saccharide concatenation; as well as their pharmaceutically acceptable salts, and their use as medicines.
    Type: Application
    Filed: July 16, 2010
    Publication date: November 4, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Philippe DUCHAUSSOY, Jean Pascal HERAULT, Jean Marc HERBERT, Maurice PETITOU, Pierre SAVI
  • Patent number: 7803811
    Abstract: The present invention relates to novel 1,2,3-substituted indolizine derivative which are inhibitors of fibroblast growth factors, to methods or preparing such derivatives, to pharmaceutical compositions comprising such derivatives, and to methods of treatment comprising such derivatives.
    Type: Grant
    Filed: August 26, 2008
    Date of Patent: September 28, 2010
    Assignee: Sanofi-Aventis
    Inventors: Alain Badorc, Francoise Bono, Marie-Francoise Bordes, Nathalie Guillo, Jean-Marc Herbert
  • Patent number: 7622488
    Abstract: This invention relates to use of a pyrazole-derived compound that is an antagonist of cannabinoid CB1 receptors, alone or in combination with another active ingredient, for preparing medicinal products that are of use in the prevention and treatment of kidney diseases.
    Type: Grant
    Filed: August 2, 2007
    Date of Patent: November 24, 2009
    Assignee: sanofi-aventis
    Inventors: Mohammed Bensaid, Jean-Marc Herbert, Philip Janiak
  • Publication number: 20090215755
    Abstract: Use of a pyrazole-derived compound that is an antagonist for cannabinoid CB1 receptors, alone or combined with another active principal, for preparing medicinal products that are useful in the prevention and treatment of dyslipidemias and of diseases related to dyslipidemias and/or to obesity, such as metabolic syndrome, cardiovascular risks and hepatic diseases.
    Type: Application
    Filed: May 11, 2009
    Publication date: August 27, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Michele Arnone, Jean Marc Herbert, Hassan Massoud Heshmati, Philip Janiak, Mohammed Bensaid
  • Patent number: 7553845
    Abstract: The invention is directed to a compound of formula I, wherein R, R1, R2, R3 and R4 are as defined herein, or a pharmaceutically acceptable salt thereof, and its pharmaceutically composition, preparation and uses as an inhibitor of FGFs (fibroblast growth factors).
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: June 30, 2009
    Assignee: sanofi-aventis
    Inventors: Chantal Alcouffe, Alain Badorc, Francoise Bono, Marie-Francoise Bordes, Nathalie Guillo, Jean-Marc Herbert
  • Publication number: 20090023770
    Abstract: The present invention relates to novel 1,2,3-substituted indolizine derivative which are inhibitors of fibroblast growth factors, to methods or preparing such derivatives, to pharmaceutical compositions comprising such derivatives, and to methods of treatment comprising such derivatives.
    Type: Application
    Filed: August 26, 2008
    Publication date: January 22, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Alain BADORC, Francoise BONO, Marie-Francoise BORDES, Nathalie GUILLO, Jean-Marc HERBERT
  • Patent number: 7468368
    Abstract: The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) in which: n is 1 or 2; p is 1 or 2; R1 represents a halogen atom; a trifluoromethyl radical; a (C1-C4)alkyl; a (C1-C4)alkoxy; a trifluoromethoxy radical; R2 represents a hydrogen atom or a halogen atom; R3 represents a hydrogen atom; a group —OR5; a group —CH2OR5; a group —NR6R7; a group —NR8COR9; a group —NR8CONR10R11; a group —CH2NR12R13; a group —CH2NR8CONR14R15; a (C1-C4)alkoxycarbonyl; a group —CONR16R17; or else R3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring; R4 represents an aromatic group selected from: the said aromatic groups being unsubstituted or being mono- or disubstituted by a substituent selected independently from a halogen atom; a (C1-C4)alkyl; a (C1-C4)alkoxy; a trifluoromethyl radical; Preparation process and therapeutic application.
    Type: Grant
    Filed: June 5, 2003
    Date of Patent: December 23, 2008
    Assignee: Sanofi Aventis
    Inventors: Françoise Bono, Michaël Bosch, Victor Dos Santos, Jean-Marc Herbert, Dino Nisato, Bernard Tonnerre, Jean Wagnon
  • Patent number: 7442708
    Abstract: Compounds of formula I or salts thereof: in which R1 represents —OH, (C1-C5)alkoxy, carboxyl, (C2-C6)alkoxycarbonyl, —NR5R6, —NH—SO2-Alk, —NH—SO2-Ph, —NH—CO-Ph, —N(Alk)-CO-Ph, —NH—CO—NH-Ph, —NH—CO-Alk, —NH—CO2-Alk, —O—(CH2)n-cAlk, —O-Alk-COOR7, —O-Alk-O—R8, —O-Alk-OH, —O-Alk-C(NH2):NOH, —O-Alk-NR5R6, —O-Alk-CN, —O—(CH2)n-Ph, —O-Alk-CO—NR5R6, —CO—NH—(CH2)m—COOR7, —CO—NH-Alk R2 represents H, (C1-C5)alkyl, (C1-C5)alkyl halide, (C3-C6)cycloalkyl or phenyl which is optionally substituted, A represents —CO—, —SO— or —SO2—, R3 and R4 which are identical or different, each represent H, (C1-C5)alkoxy, amino, carboxyl, (C2-C6)alkoxycarbonyl, —OH, nitro, hydroxyamino, -Alk-COOR7, —NR5R6, —NH-Alk-COOR7, —NH—COO-Alk, —N(R11)—SO2-Alk-NR9R10, —N(R11)—SO2-Alk, —N(R11)-Alk-NR5R6, —N(R11)—CO-Alk-NR9R10, —N(R11)—CO-Alk, —N(R11)—CO—CF3, —NH-Alk-HetN, —O-Alk-NR9R10, —O-Alk-CO—NR5R6, —O-Alk-HetN, or R3 and R4 form together a 5- to 6-membered unsaturated heterocycle, are inhibitors of basic fibroblast growth factors.
    Type: Grant
    Filed: April 2, 2003
    Date of Patent: October 28, 2008
    Assignee: Sanofi-Aventis
    Inventors: Alain Badorc, Francoise Bono, Marie-Francoise Bordes, Nathalie Guillo, Jean-Marc Herbert
  • Patent number: 7320982
    Abstract: The invention relates to the use of a compound of formula (I): for the preparation of pharmaceutical compositions for increasing the circulating, cellular and extracellular levels of TGF-?1.
    Type: Grant
    Filed: February 5, 2004
    Date of Patent: January 22, 2008
    Assignee: sanofi-aventis
    Inventors: Françoise Bono-Combie, Jacqueline Fournier, Jean Marc Herbert, Isabelle Lamarche, Umberto Guzzi
  • Publication number: 20080015228
    Abstract: This invention relates to use of a pyrazole-derived compound that is an antagonist of cannabinoid CB1 receptors, alone or in combination with another active ingredient, for preparing medicinal products that are of use in the prevention and treatment of kidney diseases.
    Type: Application
    Filed: August 2, 2007
    Publication date: January 17, 2008
    Applicant: SANOFI-AVENTIS
    Inventors: Mohammed BENSAID, Jean Marc HERBERT, Philip JANIAK
  • Patent number: 7294628
    Abstract: The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) in which: n is 1 or 2; R1 represents a halogen atom; a trifluoromethyl radical; a (C1-C4) alkyl; a (C1-C4)alkoxy; a trifluoromethoxy radical; R2 represents a hydrogen atom or a halogen atom; R3 represents a hydrogen atom; a group —OR5; a group —CH2OR5; a group —NR6R7; a group —NR8COR9; a group —NR8CONR10R11; a group —CH2NR12R13; a group —CH2NR8CONR14R15; a (C1-C4)alkoxycarbonyl; a group —CONR16R17; or else R3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring; R4 represents the aromatic group 1,3-thiazol-2-yl of formula: Preparation process and therapeutic application.
    Type: Grant
    Filed: June 5, 2003
    Date of Patent: November 13, 2007
    Assignee: Sanofi-Aventis
    Inventors: Françoise Bono, Michaël Bosch, Victor Dos Santos, Jean-Marc Herbert, Dino Nisato, Bernard Tonnerre, Jean Wagnon
  • Publication number: 20070072907
    Abstract: Use of a pyrazole-derived compound that is an antagonist for cannabinoid CB1 receptors, alone or combined with another active principal, for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and/or to obesity, such as metabolic syndrome, cardiovascular risks and hepatic diseases.
    Type: Application
    Filed: April 24, 2006
    Publication date: March 29, 2007
    Applicant: sanofi-aventis
    Inventors: Michele Arnone, Jean Marc Herbert, Hassan Heshmati, Philip Janiak, Mohammed Bensaid